Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Mol Cell Biol. 2012 Oct;32(19):3913-24. doi: 10.1128/MCB.00068-12. Epub 2012 Jul 30.
Identification of genes that are upregulated during mammary epithelial cell morphogenesis may reveal novel regulators of tumorigenesis. We have demonstrated that gene expression programs in mammary epithelial cells grown in monolayer cultures differ significantly from those in three-dimensional (3D) cultures. We identify a protein tyrosine phosphate, PTPRO, that was upregulated in mature MCF-10A mammary epithelial 3D structures but had low to undetectable levels in monolayer cultures. Downregulation of PTPRO by RNA interference inhibited proliferation arrest during morphogenesis. Low levels of PTPRO expression correlated with reduced survival for breast cancer patients, suggesting a tumor suppressor function. Furthermore, we showed that the receptor tyrosine kinase ErbB2/HER2 is a direct substrate of PTPRO and that loss of PTPRO increased ErbB2-induced cell proliferation and transformation, together with tyrosine phosphorylation of ErbB2. Moreover, in patients with ErbB2-positive breast tumors, low PTPRO expression correlated with poor clinical prognosis compared to ErbB2-positive patients with high levels of PTPRO. Thus, PTPRO is a novel regulator of ErbB2 signaling, a potential tumor suppressor, and a novel prognostic marker for patients with ErbB2-positive breast cancers. We have identified the protein tyrosine phosphatase PTPRO as a regulator of three-dimensional epithelial morphogenesis of mammary epithelial cells and as a regulator of ErbB2-mediated transformation. In addition, we demonstrated that ErbB2 is a direct substrate of PTPRO and that decreased expression of PTPRO predicts poor prognosis for ErbB2-positive breast cancer patients. Thus, our results identify PTPRO as a novel regulator of mammary epithelial transformation, a potential tumor suppressor, and a predictive biomarker for breast cancer.
鉴定在乳腺上皮细胞形态发生过程中上调的基因可能揭示肿瘤发生的新调节因子。我们已经证明,在单层培养的乳腺上皮细胞中生长的基因表达程序与在三维(3D)培养中的显著不同。我们鉴定出一种蛋白质酪氨酸磷酸酶,PTPRO,在成熟 MCF-10A 乳腺上皮 3D 结构中上调,但在单层培养中水平低至无法检测。通过 RNA 干扰下调 PTPRO 抑制形态发生过程中的增殖停滞。PTPRO 的低表达与乳腺癌患者的生存减少相关,表明其具有肿瘤抑制功能。此外,我们表明受体酪氨酸激酶 ErbB2/HER2 是 PTPRO 的直接底物,并且 PTPRO 的丢失增加了 ErbB2 诱导的细胞增殖和转化,以及 ErbB2 的酪氨酸磷酸化。此外,在 ErbB2 阳性乳腺癌患者中,与 PTPRO 高水平的 ErbB2 阳性患者相比,低表达 PTPRO 与不良临床预后相关。因此,PTPRO 是 ErbB2 信号的新型调节剂,是潜在的肿瘤抑制因子,也是 ErbB2 阳性乳腺癌患者的新型预后标志物。我们已经鉴定出蛋白酪氨酸磷酸酶 PTPRO 作为乳腺上皮细胞三维上皮形态发生的调节剂和 ErbB2 介导的转化的调节剂。此外,我们证明 ErbB2 是 PTPRO 的直接底物,并且 PTPRO 的表达降低预示着 ErbB2 阳性乳腺癌患者的预后不良。因此,我们的结果表明 PTPRO 是乳腺上皮转化的新型调节剂、潜在的肿瘤抑制因子和乳腺癌的预测生物标志物。